

**PB 47 of 2025**

National Health (Minimum Stockholding) Amendment Determination (No. 4) 2025

I, Rebecca Richardson, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 16 April 2025

Rebecca Richardson

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing 1 May 2025 2

National Health (Minimum Stockholding) Determination 2023 2

Schedule 2—Amendments commencing 1 October 2025 5

National Health (Minimum Stockholding) Determination 2023 5

1 Name

 (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 4) 2025*.

 (2) This instrument may also be cited as PB 47 of 2025.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 May 2025. | 1 May 2025 |
| 2. Schedule 1 | 1 May 2025. | 1 May 2025 |
| 3. Schedule 2 | 1 October 2025. | 1 October 2025 |

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 May 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefotaxime | Powder for injection 1 g (as sodium) | Injection | DBL Cefotaxime | between 1 April 2025 and 30 April 2025—0 months stock by reference to usual demand |

2 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | Entecavir Viatris | after 28 February 2025— 4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Erythromycin | Capsule 250 mg (containing enteric coated pellets) | Oral | Mayne Pharma Erythromycin | 2 months stock by reference to usual demand |

3 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methoxyflurane | Liquid for inhalation 999 mg per g, 3 ml (with inhaler) | Inhalation by mouth | Penthrox (Combination Pack) | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methylprednisolone | Powder for injection 1 g (as sodium succinate) | Injection | Solu-Medrol | between 1 May 2025 and 31 May 2025—0 months stock by reference to usual demand |

4 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methylprednisolone | Powder for injection 40 mg (as sodium succinate) with diluent | Injection | Solu-Medrol | between 1 April 2025 and 30 April 2025—0 months stock by reference to usual demand |

5 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | APX-Montelukast | 4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Montelukast Viatris | after 31 August 2025—4 months stock by reference to usual demand of both Montelukast Viatris and Montelukast Mylan added together |

6 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | Indosyl Mono 2 | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | Indosyl Mono 4 | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 8 mg | Oral | Indosyl Mono 8 | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Indosyl Combi 4/1.25 | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg-3 mg per mL, 15 mL | Application to the Eye | Optix | between 1 February 2025 and 30 April 2025—0 months stock by reference to usual demand |

8 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sumatriptan | Tablet 50 mg (as succinate) | Oral | APO‑Sumatriptan | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sumatriptan | Tablet 50 mg (as succinate) | Oral | Imigran | between 1 April 2025 and 30 June 2025—0 months stock by reference to usual demand |
| Sumatriptan | Tablet 50 mg (as succinate) | Oral | Imigran Migraine | between 1 April 2025 and 30 June 2025—0 months stock by reference to usual demand |

Schedule 2—Amendments commencing 1 October 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Chlortalidone | Tablet 25 mg | Oral | Hygroton 25 | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Choriogonadotropin alfa | Solution for injection 250 micrograms in 0.5 mL pre-filled pen | Injection | Ovidrel | 6 months stock by reference to usual PBS demand |

2 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Levetiracetam | Tablet 250 mg | Oral | Levetiracetam Viatris | after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Levonorgestrel | Intrauterine drug delivery system 52 mg | Intrauterine | Mirena | 6 months stock by reference to usual PBS demand |

3 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Triglycerides - medium chain, formula | Oral powder 400 g (Lipistart) | Oral | Lipistart | 0 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Triglycerides, long chain with glucose polymer | Oral liquid 1 L, 6 (ProZero) | Oral | ProZero | 6 months stock by reference to usual PBS demand |